Kevin Sharer tells often-hostile investors that the company is off to a good start this year.
The beleaguered chief executive of biotech giant Amgen Inc. confronted an often testy group of shareholders Wednesday, his first annual meeting with investors since the company's fortunes took a hard turn last summer.
...
Anytime
